TARS - צמיחת הכנסות שנתית ב-12 החודשים האחרונים Tarsus Pharmaceuticals

The annual growth rate of trailing twelve months (LTM) revenue on the GURU.Markets base chart shows that the metric for Tarsus Pharmaceuticals (TARS) is 86.00. Patent protection and FDA approval create a powerful regulatory barrier for competitors. Tarsus Pharmaceuticals (TARS) possesses pricing power due to the lack of comparable drugs for blepharitis. The integration of this unique therapy into demodicosis treatment protocols establishes a new, unrivaled standard in ophthalmology.
Tarsus Pharmaceuticals - פילוחים אנליטיים ומדדי מפתח (TARS)

This metric reflects revenue dynamics over the last twelve months, capturing the consensus estimate of sales growth rates compared to the same period last year. For Tarsus Pharmaceuticals (TARS), this 12-month YoY sales trend confirms the monetization of a unique drug with inelastic demand. The lack of alternatives provides the company with pricing power and stable market expansion. However, it is critical for investors to correlate this growth with the cost side to mitigate risks in the event of a demand slowdown.